Cytotoxic effects of benzbromarone and Its 1′-hydroxy metabolite in human hepatocarcinoma FLC4 cells cultured on micro-space cell culture plates

Drug Metabolism and Pharmacokinetics

Volumn 28, Issue 3, 2013, Pages 265-268

  Kobayashi, Kaoru ^a   Kajiwara, Eri ^a   Ishikawa, Masayuki ^a   Mimura, Hanaka ^a   Oka, Hidenobu ^a,b   Ejiri, Yoko ^c   Hosoda, Masaya ^c   Chiba, Kan ^a  

^a CHIBA UNIVERSITY   (Japan)

^b Torii Nihonbashi Building   (Japan)

^c KURARAY CO LTD   (Japan)

Author keywords

Benzbromarone; CYP2C9; CYP3A; Glutathione; Liver injury

Indexed keywords

1 HYDROXYBENZBROMARONE; 6 HYDROXYBENZBROMARONE; ACETYLCYSTEINE; BENZBROMARONE; BUTHIONINE SULFOXIMINE; CYTOCHROME P450 3A; DICOUMAROL; DRUG METABOLITE; GLUTATHIONE; ITRACONAZOLE; KETOCONAZOLE; QUINONE DERIVATIVE; TERT BUTYLHYDROQUINONE; TIENILIC ACID; UNCLASSIFIED DRUG;

CARCINOMA CELL; CONTROLLED STUDY; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; NOTE;

EID: 84879349103     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-12-NT-105     Document Type: Article

References (18)

1. van der Klauw, M. M., Houtman, P. M., Stricker, B. H. and Spoelstra, P.: Hepatic injury caused by benzbromarone. J. Hepatol., 20: 376-379 (1994).
2. Arai, M., Yokosuka, O., Fujiwara, K., Kojima, H., Kanda, T., Hirasawa, H. and Saisho, H.: Fulminant hepatic failure associated with benzbromarone treatment: a case report. J. Gastroenterol. Hepatol., 17: 625-626 (2002).
3. Wagayama, H., Shiraki, K., Sugimoto, K., Fujikawa, K., Shimizu, A., Takase, K., Nakano, T. and Tameda, Y.: Fatal fulminant hepatic failure associated with benzbromarone. J. Hepatol., 32: 874 (2000).
4. Suzuki, T., Suzuki, T., Kimura, M., Shinoda, M., Fujita, T., Miyake, N., Yamamoto, S. and Tashiro, K.: A case of fulminant hepatitis, possibly caused by benzbromarone. Nippon Shokakibyo Gakkai Zasshi, 98: 421-425 (2001).
5. Li, A. P.: A review of the common properties of drugs with idiosyncratic hepatotoxicity and the "multiple determinant hypothesis" for the manifestation of idiosyncratic drug toxicity. Chem. Biol. Interact., 142: 7-23 (2002).
6. McDonald, M. G. and Rettie, A. E.: Sequential metabolism and bioactivation of the hepatotoxin benzbromarone: formation of glutathione adducts from a catechol intermediate. Chem. Res. Toxicol., 20: 1833-1842 (2007).
7. Kobayashi, K., Kajiwara, E., Ishikawa, M., Oka, H. and Chiba, K.: Identification of CYP isozymes involved in benzbromarone metabolism in human liver microsomes. Biopharm. Drug Dispos., 33: 466-473 (2012).
8. Iwamura, A., Fukami, T., Hosomi, H., Nakajima, M. and Yokoi, T.: CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay. Drug Metab. Dispos., 39: 838-846 (2011).
9. Broekhuysen, J., Pacco, M., Sion, R., Demeulenaere, L. and van Hee, M.: Metabolism of benzbromarone in man. Eur. J. Clin. Pharmacol., 4: 125-130 (1972).
10. De Vries, J. X., Walter-Sack, I., Ittensohn, A. and Weber, E.: The isolation, identification and structure of a new hydroxylated metabolite of benzbromarone in man. Xenobiotica, 19: 1461-1470 (1989).
11. Kobayashi, K., Yoshida, A., Ejiri, Y., Takagi, S., Mimura, H., Hosoda, M., Matsuura, T. and Chiba, K.: Increased expression of drugmetabolizing enzymes in human hepatocarcinoma FLC-4 cells cultured on micro-space cell culture plates. Drug Metab. Pharmacokinet., 27: 478-485 (2012).
12. Lee, H. R., Cho, J. M., Shin, D. H., Yong, C. S., Choi, H. G., Wakabayashi, N. and Kwak, M. K.: Adaptive response to GSH depletion and resistance to L-buthionine-(S, R)-sulfoximine: involvement of Nrf2 activation. Mol. Cell. Biochem., 318: 23-31 (2008).
13. Jurima-Romet, M., Huang, H. S., Beck, D. J. and Li, A. P.: Evaluation of drug interactions in intact hepatocytes: Inhibitors of terfenadine metabolism. Toxicol. In Vitro, 10: 655-663 (1996).
14. McGinnity, D. F., Berry, A. J., Kenny, J. R., Grime, K. and Riley, R. J.: Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes. Drug Metab. Dispos., 34: 1291-1300 (2006).
15. Preusch, P. C., Siegel, D., Gibson, N. W. and Ross, D.: A note on the inhibition of DT-diaphorase by dicoumarol. Free Radic. Biol. Med., 11: 77-80 (1991).
16. Manov, I., Hirsh, M. and Iancu, T. C.: N-acetylcysteine does not protect HepG2 cells against acetaminophen-induced apoptosis. Basic Clin. Pharmacol. Toxicol., 94: 213-225 (2004).
17. Keum, Y. S., Han, Y. H., Liew, C., Kim, J. H., Xu, C., Yuan, X., Shakarjian, M. P., Chong, S. and Kong, A. N.: Induction of heme oxygenase-1 (HO-1) and NAD[P]H: quinone oxidoreductase 1 (NQO1) by a phenolic antioxidant, butylated hydroxyanisole (BHA) and its metabolite, tert-butylhydroquinone (tBHQ) in primary-cultured human and rat hepatocytes. Pharm. Res., 23: 2586-2594 (2006).
18. Lu, S. C.: Regulation of hepatic glutathione synthesis: current concepts and controversies. FASEB J., 13: 1169-1183 (1999).